S&P 500   3,956.19 (+0.57%)
DOW   33,788.52 (+0.57%)
QQQ   283.23 (+0.96%)
AAPL   142.61 (+1.18%)
MSFT   246.78 (+0.99%)
META   115.31 (+1.21%)
GOOGL   93.76 (-1.24%)
AMZN   89.73 (+1.44%)
TSLA   170.91 (-1.80%)
NVDA   167.29 (+3.78%)
NIO   13.23 (+5.17%)
BABA   93.15 (+5.46%)
AMD   70.44 (+0.43%)
T   19.22 (-0.41%)
MU   55.40 (+2.94%)
CGC   3.18 (-1.85%)
F   13.17 (+0.53%)
GE   84.25 (-0.88%)
DIS   92.54 (+0.42%)
AMC   6.25 (+3.31%)
PYPL   75.31 (+1.20%)
PFE   50.78 (+1.07%)
NFLX   308.67 (+0.08%)
S&P 500   3,956.19 (+0.57%)
DOW   33,788.52 (+0.57%)
QQQ   283.23 (+0.96%)
AAPL   142.61 (+1.18%)
MSFT   246.78 (+0.99%)
META   115.31 (+1.21%)
GOOGL   93.76 (-1.24%)
AMZN   89.73 (+1.44%)
TSLA   170.91 (-1.80%)
NVDA   167.29 (+3.78%)
NIO   13.23 (+5.17%)
BABA   93.15 (+5.46%)
AMD   70.44 (+0.43%)
T   19.22 (-0.41%)
MU   55.40 (+2.94%)
CGC   3.18 (-1.85%)
F   13.17 (+0.53%)
GE   84.25 (-0.88%)
DIS   92.54 (+0.42%)
AMC   6.25 (+3.31%)
PYPL   75.31 (+1.20%)
PFE   50.78 (+1.07%)
NFLX   308.67 (+0.08%)
S&P 500   3,956.19 (+0.57%)
DOW   33,788.52 (+0.57%)
QQQ   283.23 (+0.96%)
AAPL   142.61 (+1.18%)
MSFT   246.78 (+0.99%)
META   115.31 (+1.21%)
GOOGL   93.76 (-1.24%)
AMZN   89.73 (+1.44%)
TSLA   170.91 (-1.80%)
NVDA   167.29 (+3.78%)
NIO   13.23 (+5.17%)
BABA   93.15 (+5.46%)
AMD   70.44 (+0.43%)
T   19.22 (-0.41%)
MU   55.40 (+2.94%)
CGC   3.18 (-1.85%)
F   13.17 (+0.53%)
GE   84.25 (-0.88%)
DIS   92.54 (+0.42%)
AMC   6.25 (+3.31%)
PYPL   75.31 (+1.20%)
PFE   50.78 (+1.07%)
NFLX   308.67 (+0.08%)
S&P 500   3,956.19 (+0.57%)
DOW   33,788.52 (+0.57%)
QQQ   283.23 (+0.96%)
AAPL   142.61 (+1.18%)
MSFT   246.78 (+0.99%)
META   115.31 (+1.21%)
GOOGL   93.76 (-1.24%)
AMZN   89.73 (+1.44%)
TSLA   170.91 (-1.80%)
NVDA   167.29 (+3.78%)
NIO   13.23 (+5.17%)
BABA   93.15 (+5.46%)
AMD   70.44 (+0.43%)
T   19.22 (-0.41%)
MU   55.40 (+2.94%)
CGC   3.18 (-1.85%)
F   13.17 (+0.53%)
GE   84.25 (-0.88%)
DIS   92.54 (+0.42%)
AMC   6.25 (+3.31%)
PYPL   75.31 (+1.20%)
PFE   50.78 (+1.07%)
NFLX   308.67 (+0.08%)
OTCMKTS:LXRP

Lexaria Bioscience - LXRP Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
$0.22
▼
$0.22
52-Week Range
N/A
Volume
2.15 million shs
Average Volume
608,350 shs
Market Capitalization
$20.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
LXRP stock logo

About Lexaria Bioscience (OTCMKTS:LXRP) Stock

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

Receive LXRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

LXRP Stock News Headlines

November 21, 2022 | finance.yahoo.com
Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies
November 3, 2022 | proactiveinvestors.com
Lexaria Bioscience progresses with hypertension and oral nicotine studies using DehydraTECH
October 31, 2022 | msn.com
LEXX: DehydraTECH CBD HYPER-H21-4 Results
October 28, 2022 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria's Human Clinical Hypertension Study a Success
September 2, 2022 | apnews.com
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
August 12, 2022 | marketwatch.com
TinyGemsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Discusses Biotech Industry Valuation Metrics
August 10, 2022 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
August 10, 2022 | msn.com
Lexaria Gets FDA's Positive Feedback On Pre-Clinical Trial Of Hypertension Candidate
July 27, 2022 | apnews.com
Lexaria’s DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 15, 2022 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria's Human Nicotine Study Nearing Start Date
July 14, 2022 | apnews.com
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
July 14, 2022 | baystreet.ca
Lexaria Flat on Patent News from Japan
July 13, 2022 | finance.yahoo.com
Lexaria's Human Nicotine Study Nearing Start Date
June 21, 2022 | marketwatch.com
Lexaria Bioscience Shares Rise 17% After Two Deals With BevNology
June 6, 2022 | finance.yahoo.com
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
June 6, 2022 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
June 6, 2022 | baystreet.ca
Lexaria Edges up on FDA Deal
June 6, 2022 | seekingalpha.com
Lexaria files pre-IND meeting request with FDA for its CBD-based hypertension treatment
June 3, 2022 | benzinga.com
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
June 2, 2022 | apnews.com
Lexaria Grants License to Valcon Medical for the European Market
April 14, 2022 | marketwatch.com
Lexaria Bioscience Shares Rise 15% After Positive Data for Study for Hypertension Treatment
February 11, 2022 | benzinga.com
Lexaria Technology Shows Promise In Improving Performance Of ED Drugs
February 2, 2022 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
January 27, 2022 | finance.yahoo.com
Lexaria Provides Annual Letter From the CEO
January 27, 2022 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Provides Annual Letter From the CEO
See More Headlines

Receive LXRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Metal Mining
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:LXRP
CUSIP
52886N208
CIK
1348362
Web
www.lexariabioscience.com
Phone
(250) 765-6424
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,090,000.00
Net Margins
-1,046.77%
Pretax Margin
N/A
Return on Equity
-157.62%
Return on Assets
-148.09%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
8.52
Quick Ratio
8.01

Sales & Book Value

Annual Sales
$380,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
89,587,000
Free Float
N/A
Market Cap
$20.15 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Christopher A. Bunka (Age 58)
    Chairman & CEO
    Comp: $300.8k
  • Mr. John M. Docherty (Age 51)
    Pres & Director
    Comp: $242.52k
  • Mr. Allan Spissinger C.A. (Age 51)
    CPA, CFO, Corp. Sec. & Treasurer
    Comp: $121.66k
  • Vanessa Carle
    Head of Legal
  • Dr. Philip Ainslie
    Advisor & Consultant

Key Competitors

View All Competitors













LXRP Stock - Frequently Asked Questions

What other stocks do shareholders of Lexaria Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexaria Bioscience investors own include Aurora Cannabis (ACBFF), OrganiGram (OGI), Cronos Group (CRON), Aphria (APHQF), CV Sciences (CVSI), Auxly Cannabis Group (CBWTF), iAnthus Capital (ITHUF), Alibaba Group (BABA) and GW Pharmaceuticals (GWPH).

What is Lexaria Bioscience's stock symbol?

Lexaria Bioscience trades on the OTCMKTS under the ticker symbol "LXRP."

How do I buy shares of Lexaria Bioscience?

Shares of LXRP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Lexaria Bioscience make?

Lexaria Bioscience (OTCMKTS:LXRP) has a market capitalization of $0.00 and generates $380,000.00 in revenue each year.

How can I contact Lexaria Bioscience?

Lexaria Bioscience's mailing address is 100 - 740 MCCURDY ROAD, KELOWNA A1, V1X 2P7. The official website for the company is www.lexariabioscience.com. The oil and gas exploration company can be reached via phone at (250) 765-6424 or via email at info@lexariabioscience.com.

This page (OTCMKTS:LXRP) was last updated on 12/8/2022 by MarketBeat.com Staff